MITCHELL H. DRIESMAN, M.D.

FAIRFIELD, CT

Research Active
Internal Medicine - Interventional Cardiology NPI registered 21+ years 2 publications 2008 – 2013 NPI: 1578568382
Internal Medicine - Interventional Cardiology Internal Medicine - Cardiovascular Disease
Pilot ProjectsCoronary AngiographyPolysaccharidesAnticoagulantsPercutaneous Coronary InterventionAcute Coronary SyndromeHeparinRecombinant ProteinsAngioplasty, Balloon, CoronaryHemorrhagePeptide FragmentsCoated Materials, BiocompatibleHirudinsAntithrombinsFondaparinux

Practice Location

1305 POST RD
FAIRFIELD, CT 06824-6016

Phone: (203) 292-2000

What does MITCHELL DRIESMAN research?

Mitchell H. Driesman studies treatments for heart conditions, especially looking at the use of anticoagulants (medications that help prevent blood clots) and the effectiveness of stents (tiny tubes inserted to keep blood vessels open). He examines how different medications, like bivalirudin and unfractionated heparin, compare in safety during procedures for acute coronary syndrome, a serious heart condition. He also explores how various techniques in stent placement can impact longer-term patient safety and recovery, providing valuable insights to improve heart treatments.

Key findings

  • In a study with 100 patients, major bleeding occurred in only 1 patient (2%) treated with bivalirudin, while none experienced major bleeding with unfractionated heparin, indicating similar safety for both anticoagulants.
  • From the STLLR trial involving 1,557 patients, 66.5% experienced geographic miss (GM) during sirolimus-eluting stent procedures, which increases the risk of needing additional procedures (5.1% with GM vs. 2.5% without) and heart attacks (2.4% with GM vs. 0.8% without).
  • The findings emphasize the need for enhanced techniques in stent placement to reduce complications and improve the chances of successful long-term outcomes for patients.

Frequently asked questions

Does Dr. Driesman study acute coronary syndrome?
Yes, he specifically researches treatments for acute coronary syndrome, including the safety of anticoagulants during procedures.
What treatments has Dr. Driesman researched?
He has researched anticoagulant medications like bivalirudin and unfractionated heparin, as well as sirolimus-eluting stents used for heart conditions.
Is Dr. Driesman's work relevant to patients undergoing heart procedures?
Absolutely, his findings aim to improve safety and effectiveness for patients undergoing procedures like percutaneous coronary intervention and stent placements.

Publications in plain English

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

2013

Journal of interventional cardiology

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J +5 more

Plain English
This study looked at two anticoagulant medications—bivalirudin and unfractionated heparin (UFH)—to see which is safer for patients with acute coronary syndrome (ACS) undergoing a procedure called percutaneous coronary intervention (PCI) after being treated with fondaparinux. Among 100 patients, major bleeding occurred in just one patient treated with bivalirudin (2%) and none in the UFH group. The findings indicate that bivalirudin is as safe as UFH for these patients, which is crucial for improving treatment options. Who this helps: This helps doctors and their patients with acute coronary syndrome undergoing PCI.

PubMed

Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial).

2008

The American journal of cardiology

Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A +9 more

Plain English
This study looked at how different techniques used during the placement of sirolimus-eluting stents (SESs) affect long-term success and safety in patients with heart issues. Researchers found that about 66.5% of the 1,557 patients experienced a problem called geographic miss (GM), which can lead to higher risks of needing more heart procedures (5.1% in the GM group compared to 2.5% in the group without GM) and even heart attacks (2.4% for those with GM versus 0.8% for those without). This highlights the importance of improving the methods used in stent placements to ensure better outcomes for patients. Who this helps: This helps patients undergoing stent procedures and their doctors.

PubMed

Frequent Co-Authors

Ron Waksman Olivier Bertrand Luis Gruberg Joseph Rossi Shamir Mehta Stacy Swymelar Danny Dvir Zhenyi Xue Rebecca Torguson Marco A Costa

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.